Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW OKs New Indication for Nesp, Pediatric Dosages for Cancidas
December 19, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
- Drug Makers Present Cases in Which PI Trials in Japanese Could Be Omitted in Multinational Studies: PMDA Workshop
December 17, 2014
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- Editor’s Pick: Five Healthcare News Headlines for Dec. 1 - 14
December 15, 2014
- JPMA Will Work to Secure Quality, Transparency of Clinical Research for Purpose of Advertising: Vice President
December 15, 2014
- LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
- Ryukaikon Members Hail High Price Settlements, but Fret over Fallout from Penalty Fee Cuts
December 11, 2014
- Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
- Eculizumab, Bosentan Designated as Orphan Drugs
December 10, 2014
- Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
- Paclitaxel OK’ed for External Review under Fast-Track Senshin-Iryo Scheme for Cancer Drugs
December 8, 2014
- Five SGLT-2 Inhibitors Undergoing Evaluation for Risk of Dehydration: PMDA
December 8, 2014
- Fee Cut Rule Needs Review before Debate on Annual NHI Price Revisions: MHLW Exec
December 4, 2014
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…